Exane Derivatives’s Iovance Biotherapeutics IOVA Stock Holding History

Exane Derivatives’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$221	Hold	20	–	–	﹤0.01%	663
2022 Q1	$333	Hold	20	–	–	﹤0.01%	914
2021 Q4	$382	Hold	20	–	–	﹤0.01%	800
2021 Q3	$493	Hold	20	–	–	﹤0.01%	940
2021 Q2	$495	Hold	20	–	–	﹤0.01%	944
2021 Q1	$633	Hold	20	–	–	﹤0.01%	774
2020 Q4	$928	Hold	20	–	–	﹤0.01%	685
2020 Q3	$658	Hold	20	–	–	﹤0.01%	659
2020 Q2	$549	Hold	20	–	–	﹤0.01%	607
2020 Q1	$599	Hold	20	–	–	﹤0.01%	578
2019 Q4	$473	Sell	20 -374	-95%	-$8.51K	﹤0.01%	615
2019 Q3	$7.17K	Sell	394 -7,406	-95%	-$164K	﹤0.01%	441
2019 Q2	$191K	Buy	+7,800	New	+$117K	0.03%	282

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Exane Derivatives's IOVA Position: Q2 2022 in Review

Exane Derivatives held its Iovance Biotherapeutics (IOVA) position steady in Q2 2022 at 20 shares worth $221. The position accounts for ﹤0.01% of the portfolio, ranked #663.

Exane Derivatives first reported a position in IOVA in Q2 2019 and has held it in 13 quarters since. The position peaked at $191K in Q2 2019. 237 funds tracked by Wall St. Rank hold IOVA as of Q2 2022.

Exane Derivatives held 20 shares of Iovance Biotherapeutics worth $221 as of Q2 2022.
Exane Derivatives left its Iovance Biotherapeutics share count unchanged in Q2 2022.
Iovance Biotherapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #663 holding.
Exane Derivatives first reported a position in Iovance Biotherapeutics in Q2 2019 and has held it in 13 quarters since.
Exane Derivatives's Iovance Biotherapeutics position peaked at $191K in Q2 2019.
237 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.